Upgrades And Downgrades
Analysts at Oppenheimer raised their rating on shares of CRISPR Therapeutics (CRSP) stock from "Perform" to "Outperform" on Tuesday.
InvestorsKeyhole Trade Alert
CRISPR Therapeutics (CRSP) Stock Upgraded to Outperform
Analysts at Oppenheimer raised their rating on shares of CRISPR Therapeutics (CRSP) stock from "Perform" to "Outperform" on Tuesday.